EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A comprehensive discovery platform for ELOVL1 small-molecule inhibitors targeting very long-chain fatty acid synthesis in adrenoleukodystrophy

Stephanie Holley, Gary Asmussen, Becky Lam, Zhonglin Zhao, Brian Freed, Lilu Guo, Zuzana Dostalova, Buyun Tang, Michael Kothe, Paul Lang, Donghui Wang, Martin Hanus und 4 weitere

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.113103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Stephanie Holley und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Sanofi, Cambridge, Massachusetts, USA. Electronic address: Stephanie.Holley@sanofi.com. Hauptthemen laut MEDLINE: Fatty Acid Elongases, Enzyme Inhibitors, Fatty Acids, Small Molecule Libraries. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, Universiteit van Amsterdam.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adrenoleukodystrophy (ALD or X-ALD) is a rare devastating neurological disease caused by mutations in the ATP binding cassette D1 (ABCD1) gene, the product of which is involved in the transport of very long-chain fatty acids (VLCFAs) into peroxisomes for degradation by β-oxidation. Deficiency in ABCD1 results in VLCFAs accumulation in many tissues, including the brain and spinal cord. Elevated VLCFA levels, specifically C26:0, are consistent biochemical markers of ALD and are implicated in the ALD pathogenesis. ALD disease is manifested by multiple phenotypes: the most severe cerebral disease (cerebral ALD, cALD), adrenomyeloneuropathy (AMN) and adrenal insufficiency (Addison disease). VLCFA accumulation is a hallmark of all ALD phenotypes, and reduction/normalization of VLCFA levels is an attractive approach for the treatment of all ALD manifestations. VLCFAs synthesis involves enzymes from elongase of very long-chain fatty acids (ELOVL) enzyme family with ELOVL1 being a rate-limiting enzyme in C26:0 synthesis, making ELOVL1 an attractive target for medical intervention in ALD via Substrate Reduction Therapy (SRT). In this paper, we describe the in vitro assays established to support medicinal chemistry efforts to develop small-molecule ELOVL1 inhibitors for ALD. Notably, we developed novel, breakthrough in vitro methods to monitor enzymatic and cellular ELOVL1 activity, enabling high-throughput screening (HTS) of Sanofi library collections. We successfully identified CNS-active, small-molecule ELOVL1 inhibitors shown to be efficacious in the reduction of C26:0 VLCFA levels in cells and multiple tissues, including brain and spinal cord, in animal models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Acid ElongasesEnzyme InhibitorsFatty AcidsSmall Molecule LibrariesAdrenoleukodystrophyHumansMaleChildCell SeparationCells, CulturedDrug DiscoverySubstrate SpecificityMicrosomesLipidomicsLipid Metabolism

Stichwörter der Autor:innen

ABCD1AMNCCALDELOVL1Fatty AcidsHTSX-ALDsmall molecule inhibitor

Substanzen

ELOVL1 protein, humanFatty Acid ElongasesEnzyme InhibitorsFatty AcidsSmall Molecule Libraries

Autor:innen und Institutionen

  • Research and Development, Sanofi, Cambridge, Massachusetts, USA. Electronic address: Stephanie.Holley@sanofi.com.
  • Research and Development, Sanofi, Cambridge, Massachusetts, USA.
  • Research and Development, Sanofi, Cambridge, Massachusetts, USA. Electronic address: Tatiana.Gladysheva@sanofi.com.

Förderung

  • Sanofi
  • Universiteit van Amsterdam

Zitieren

APA

Holley, S., Asmussen, G., Lam, B., Zhao, Z., Freed, B., Guo, L., Dostalova, Z., Tang, B., Kothe, M., Lang, P., Wang, D., Hanus, M., Belenky, A., Cromwell, M., Kloss, A., & Gladysheva, T. (2026). A comprehensive discovery platform for ELOVL1 small-molecule inhibitors targeting very long-chain fatty acid synthesis in adrenoleukodystrophy. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113103

Vancouver

Holley S, Asmussen G, Lam B, Zhao Z, Freed B, Guo L, et al. A comprehensive discovery platform for ELOVL1 small-molecule inhibitors targeting very long-chain fatty acid synthesis in adrenoleukodystrophy. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113103

BibTeX
@article{Holley2026,
  author = {Holley, Stephanie and Asmussen, Gary and Lam, Becky and Zhao, Zhonglin and Freed, Brian and Guo, Lilu and Dostalova, Zuzana and Tang, Buyun and Kothe, Michael and Lang, Paul and Wang, Donghui and Hanus, Martin and Belenky, Alexei and Cromwell, Mandy and Kloss, Alla and Gladysheva, Tatiana},
  title = {A comprehensive discovery platform for ELOVL1 small-molecule inhibitors targeting very long-chain fatty acid synthesis in adrenoleukodystrophy},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.113103}
}
Kostenlos starten →